Arthritis Research Canada at EULAR 2023
The EULAR Congress attracts more than 18,000 delegates from over 130 countries and takes place in a major European city. This year, the EULAR Congress takes place in Milan between May 31 and June 3. However, people can also attend the event virtually.
To learn about Arthritis Research Canada research presented at the EULAR European Congress of Rheumatology (Day 2), please scroll down.
Initiation of sodium-glucose cotransporter-2 inhibitors and recurrent gout flares in gout patients with type 2 diabetes: a general population-based cohort study
Using data from the BC Ministry of Health, we compared 8,150 adults with gout and type 2 diabetes who were starting two different glucose-lowering medications and found one, sodium-glucose cotransporter-2 inhibitors, was associated with lower rates of gout flares and gout-related hospitalizations and emergency department visits, as well as lower risk of heart attack. This may become a dual-purpose therapy for people with gout and diabetes.
Research Team: McCormick N, Yokose C, Wei J, Lu N, Wexler D, Avina-Zubieta JA, De Vera MA, Zhang Y, Choi HK.
Targets that work: Identifying modifiable predictors of presenteeism over one year in workers with inflammatory arthritis
We followed workers with inflammatory arthritis over 1-year and identified various factors associated with decreased productivity at work, including inflammation, fatigue, stress, insomnia and being female. On the other hand, more years of study and self-confidence in carrying out tasks at work were protective factors against loss of productivity.
Research Team: Luquini A, Xie H, Zhang W, Gignac M, Lacaille D.
